Antibiotic-Resistant Gonorrhea Surges Across Europe and Israel Faces Sharp Rise

The European Centre for Disease Prevention and Control (ECDC) has issued warnings about a significant increase in antibiotic-resistant gonorrhea cases across Europe, with local transmission now confirmed in several countries since 2025. Previously, most cases were linked to travel outside Europe, but recent data indicate the resistant strains are spreading within the continent. Countries reporting notable rises include France, Germany, Sweden, and the UK, while other nations continue to detect isolated cases.

Israel has also experienced a dramatic surge, with gonorrhea cases rising by 281% between January and September 2025 compared to the same period in 2023. Infectious disease specialist Dr. Roy Zucker from Ichilov Medical Center highlighted that the number of infections jumped from 460 to 1,755 in just two years. He emphasized the growing challenge of antibiotic resistance, noting that while oral treatments were once effective, current therapy relies mainly on injectable ceftriaxone, which is increasingly losing efficacy.

The ECDC reports that resistant strains primarily originate from Southeast Asian countries such as Cambodia, Indonesia, Thailand, and Vietnam, where these strains have caused treatment failures globally. However, the current concern is the evidence of local person-to-person transmission within Europe, signaling an early stage of wider spread. The ECDC warns that without sustained control measures, the situation could worsen.

Gonorrhea, caused by Neisseria gonorrhoeae, is one of the most common sexually transmitted bacterial infections and can lead to serious complications like pelvic inflammatory disease and infertility if untreated. Europe saw a 303% increase in reported cases over the past decade, with over 106,000 confirmed cases in 2024 alone, the highest since EU monitoring began in 2009. Globally, an estimated 82 million new infections occur annually among people aged 15 to 49.

The ECDC notes that increased testing and reporting may partly explain the rise in cases. Infection rates are highest among men aged 25 to 34 and women aged 20 to 24, with 62% of cases in 2024 among men who have sex with men. The general sexually active population remains at low risk, but risk increases with multiple or new sexual partners and unprotected sex. Travel to regions with prevalent resistant strains also raises risk.

Preventive options remain limited, as recent research published in the New England Journal of Medicine found that the meningococcal B vaccine does not protect against gonorrhea. Dr. Zucker stressed that responsible behavior, including condom use, timely testing, and early treatment, is currently the best way to curb the spread.